Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study

Neurology: Neuroimmunology and NeuroInflammation

Volumn 4, Issue 2, 2017, Pages

  Valentino, Paola ^a   Marnetto, Fabiana ^a   Granieri, Letizia ^a   Capobianco, Marco ^a   Bertolotto, Antonio ^a  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; CD19 ANTIGEN; RITUXIMAB;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELOOPTIC NEUROPATHY; OBSERVATIONAL STUDY; PREDICTION; RELAPSE; REMISSION; RETROSPECTIVE STUDY; YOUNG ADULT;

EID: 85020959823     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000317     Document Type: Article

References (34)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
2. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202: 473-477.
5. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012;11:535-544.
6. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-2200.
7. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59: 566-569.
8. Chanson JB, Alame M, Collongues N, et al. Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. Clin Dev Immunol 2013;2013: 146219.
9. Waters J, Pittock SJ, Bennet JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol 2014;5:290-303.
10. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68:1412-1420.
11. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76: 1310-1315.
12. Takahashi T, Fujihara K, Nakashima I, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006;210:307-313.
13. Takahashi T, Fujihara K, Nakashima I, et al. Antiaquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007;130: 1235-1243.
14. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072-3080.
15. Jarius S, Franciotta D, Paul F, et al. Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 2012;320:32-37.
16. Isobe N, Yonekawa T, Matsushita T, et al. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Mult Scler 2012;18:1541-1551.
17. Kim W, Lee JE, Li XF, et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler 2012;18:578-586.
18. Vodopivec I, Matiello M, Prasad S. Treatment of neuromyelitis optica. Curr Opin Ophthalmol 2015;26:476-483.
19. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17: 1225-1230.
20. Collongues N, de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 2016;9: 180-188.
21. Capobianco M, Malucchi S, Di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 2007;28:209-211.
22. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success. Mult Scler 2012;18:1022-1026.
23. Marnetto F, Granieri L, Valentino P, Capobianco M, Pautasso M, Bertolotto A. CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study. J Neuroimmunol 2014;277:127-133.
24. Granieri L, Marnetto F, Valentino P, et al. Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS One 2012; 7:e38896.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
26. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003;228:303-308.
27. Ratelade J, Verkman A. Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol 2012;44:1519-1530.
28. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6:383-392.
29. Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: Aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008;4:202-214.
30. Kovacs KT, Kalluri SR, Boza-Serrano A, et al. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. Mult Scler 2016;22: 1192-1201.
31. Nishiyama S, Ito T, Misu T, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009;72:1960-1961.
32. Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e134. doi: 10.1212/NXI.0000000000000317.
33. Makatsori M, Kiani-Alikhan S, Manson AL, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM 2014;107:821-828.
34. Roberts DM, Jones RB, Smith RM, et al. Rituximabassociated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 2015;57:60-65.